The short answer
THC has not consistently been shown to raise hydromorphone blood levels. A small oral dronabinol trial found no significant peak-level change, although some adverse effects increased with the combination.
What this answer covers
Oral synthetic delta-9 THC as dronabinol versus inhaled cannabis or other THC products; hydromorphone route/formulation boundaries.
- Supplement or preparation
- Tetrahydrocannabinol
- Medication ingredient
- hydromorphone
Measured peak levels did not significantly change
In the small pharmacokinetic subgroup of a knee-osteoarthritis trial, oral dronabinol plus hydromorphone did not significantly alter either drug’s peak concentration or time to peak. This cannot exclude other effects in larger or repeated-dose studies.
Combined effects still mattered
The combination produced more moderate adverse effects than hydromorphone alone. There was little analgesic enhancement and no clear clinical pain or physical-function benefit. A blood-level null finding is not a safety guarantee.
Laboratory predictions are not patient results
A separate metabolism study predicted possible THC interactions from laboratory inhibition. Its CBD-focused detailed simulations do not establish a measured THC effect across doses and routes.
Keep the exact product in the review
Discuss THC use with the opioid prescriber. Oral dronabinol evidence cannot be assigned directly to smoked cannabis or a different extract. Do not alter hydromorphone yourself or use timing alone as a safety measure.
Evidence and practical considerations
Absorption & effectiveness
Small direct oral trial gives contrary peak/time-to-peak null findings; laboratory prediction does not establish the broad blood-level/absorption claim. Pharmacodynamic adverse effects are separate.
- Exact scope
- Oral synthetic delta-9 THC as dronabinol versus inhaled cannabis or other THC products; hydromorphone route/formulation boundaries. with Hydromorphone RxCUI3423 IN; HCl oral immediate-release, extended-release and injected products distinguished.
- Medication form and route
- oral medication; intravenous medication; intramuscular medication; subcutaneous medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 4: original in vitro and pharmacokinetic modeling study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Human-derived microsomes and virtual healthy/cirrhotic populations.
Metabolic inhibition in vitro; PBPK predicted modest oral hydromorphone exposure increases but little intravenous change in healthy simulation.
How this applies: No measured human combination PK validation. Static and PBPK predictions differ; no universal percentage, clinical dose cut or clinical absorption finding.
No measured human combination PK validation. Static and PBPK predictions differ; no universal percentage, clinical dose cut or clinical absorption finding.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with knee osteoarthritis.
No significant peak concentration or time-to-peak change for either drug in PK subgroup. Clinical pain/function showed no significant benefit; combination had more moderate adverse effects, no serious events reported.
How this applies: 37 participants; optional PK subgroup11. Single oral synthetic THC product, not inhaled cannabis or all doses. Small peak/time analysis is not proof of unchanged total exposure in every setting.
37 participants; optional PK subgroup11. Single oral synthetic THC product, not inhaled cannabis or all doses. Small peak/time analysis is not proof of unchanged total exposure in every setting.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact hydromorphone article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: ec84be2d3b528dd0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.